In compliance with current regulations, let us know which audience you belong to:
Espansione Group, the leading medical device company offering screening and treatment solutions for ocular conditions, announced today the kick-off of the monocentric, randomized, simple blind, controlled clinical study on the efficiency of an associated treatment by Intense-Pulsed-Light OPE ® IPLand Low-Level-Light Therapy LM® LLLT with eye-light® device before laser refractive surgery to prevent dry eye disease side effect.
The research will involve a total of 62 patients affected by Dry Eye and Dry Eye After LASIK (Laser in Situ Keratomileusis): 31 of these patients will receive a preventive treatment LM® LLLT + OPE ® IPL (eye-light®) before laser refractive surgery, while the remaining patients will receive a standard care, a non-preventive treatment.
This body of work will leverage LM® LLLT + OPE ® IPL, administered via eye-light® solution, in a partnership
with University Hospital, Brest, France, led by one of the top-tier exponents of the scientific community:
> Béatrice Cochener-Lamard, MD, PhD, University Hospital of Brest, France.
The goal of the study is to demonstrate the efficiency of a preventive associated treatment by intense-pulsed-light and low-level-light therapy with eye-light® device before laser refractive surgery. Recent study confirmed the efficacy of this treatment in meibomian gland dysfunction, the predominant dry eye mechanism.
> Link to Clinical Trial Register
ABOUT REFRACTIVE SURGERY
Ametropia is the most common eye disease in people of all ages around the world. Laser refractive surgery has increased in popularity, and, unfortunately, dry eye is a common side effect, representing about 25% of patients after LASIK and 20% after SMILE. Even if symptoms are usually relieved by artificial tears, the incidence of dry eye disease and subsequent degradation in quality of life after refractive surgery is high.
SOURCE: ALEXANDRE DENOYER, ET AL. “DRY EYE DISEASE AFTER REFRACTIVE SURGERY: COMPARATIVE OUTCOMES OF SMALL INCISION LENTICULE EXTRACTION VERSUS LASIK.” OPHTHALMOLOGY 2015 APR;122(4):669-76.
ABOUT ESPANSIONE GROUP
Espansione Group is an established player in the MedTech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.
For more information, see www.espansionegroup.it
© 2023 Espansione Group, All Rights Reserved
Posted on May 17th, 2023, in Newsroom